SAFETY AND TOLERABILITY OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN SOLID TUMORS OR WITH TEMODAR® IN GLIOBLASTOMA OR OTHER RECURRENT MALIGNANT GLIOMAS OR IN COMBINATION WITH TEMODAR® AND RADIATION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA AND MALIGNANT GLIOMAS: